loading page

Forsythia suspensa (Thunb.) Vahl extract ameliorates ulcerative colitis via inhibiting NLRP3 inflammasome activation through the TLR4/MyD88/NF-κB pathway
  • +7
  • Xiao Tong,
  • Li Chen,
  • Shijun He,
  • Shuangshuang Liu,
  • Jiaying Yao,
  • Zhenguang Shao,
  • Yang Ye,
  • Sheng Yao,
  • Zemin Lin,
  • Jianping Zuo
Xiao Tong
Shanghai Institute of Materia Medica CAS
Author Profile
Li Chen
Shanghai Institute of Materia Medica CAS
Author Profile
Shijun He
Shanghai University of Traditional Chinese Medicine
Author Profile
Shuangshuang Liu
Shanghai Institute of Materia Medica CAS
Author Profile
Jiaying Yao
Jiangxi University of Traditional Chinese Medicine
Author Profile
Zhenguang Shao
Shanghai Institute of Materia Medica CAS
Author Profile
Yang Ye
Shanghai Institute of Materia Medica CAS
Author Profile
Sheng Yao
Shanghai Institute of Materia Medica CAS
Author Profile
Zemin Lin
Shanghai Institute of Materia Medica CAS
Author Profile
Jianping Zuo
Shanghai Institute of Materia Medica CAS

Corresponding Author:[email protected]

Author Profile

Abstract

Background: Ulcerative colitis (UC) is a chronic inflammatory disease caused by abnormal immune system reactions resulting in inflammation and ulcers in the large intestine. Phillygenin (PHI) is a natural compound found in Forsythia suspensa (Thunb.) Vahl, known for its various bioactivities, including anti-inflammatory, anti-obesity, and antipyretic activities. However, the potential anti-inflammatory effects of PHI on UC and its underlying mechanisms are still poorly understood. Methods: In this study, we investigated the therapeutic effects of PHI on acute UC induced by DSS and TNBS. We evaluated the effects of PHI on disease activity index, body weight, mortality, intestinal mucosal barrier, cytokine secretion, and macrophage infiltration into colon tissue using various techniques such as flow cytometry, immunofluorescence, ELISA, RT-qPCR, and Western blotting. Results: Our findings revealed that PHI has therapeutic properties in UC treatment. PHI was able to maintain body weight, reduce disease activity index and mortality, restore the intestinal mucosal barrier, and inhibit cytokine secretion. Flow cytometry assay and immunofluorescence indicated that PHI reduces macrophage infiltration into colon tissue. Additionally, both in vivo and in vitro results suggested that PHI may exert anti-inflammatory effects by downregulating the TLR4/MyD88/NF-κB pathway, inhibiting NLRP3 inflammasome activation. Conclusion: In conclusion, PHI possesses anti-inflammatory properties and has the potential as a therapeutic agent for the treatment of UC. Our study provides insights into the underlying mechanisms of PHI’s therapeutic effects and highlights the potential for further research in developing PHI-based treatments for UC.
04 May 2023Submitted to Immunity, Inflammation and Disease
04 May 2023Submission Checks Completed
04 May 2023Assigned to Editor
04 May 2023Review(s) Completed, Editorial Evaluation Pending
10 May 2023Reviewer(s) Assigned
13 Jun 2023Editorial Decision: Revise Major
31 Jul 20231st Revision Received
08 Sep 2023Submission Checks Completed
08 Sep 2023Assigned to Editor
08 Sep 2023Review(s) Completed, Editorial Evaluation Pending
08 Sep 2023Reviewer(s) Assigned
29 Sep 2023Editorial Decision: Revise Minor
29 Sep 20232nd Revision Received
18 Oct 2023Review(s) Completed, Editorial Evaluation Pending
18 Oct 2023Editorial Decision: Accept